| Not Yet Recruiting | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 / Phase 2 | 2026-02-12 |
| Recruiting | Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. Solid Advanced Tumor | Phase 1 / Phase 2 | 2026-01-31 |
| Recruiting | Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Th NSCLC, Adjuvant Drug Therapy, EGFR | Phase 2 | 2025-09-01 |
| Not Yet Recruiting | Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. Non-Small Cell Lung Cancer | Phase 2 | 2025-03-31 |
| Not Yet Recruiting | A Phase I Study of CFT8919 in Patients With Advanced NSCLC Non-Small Cell Lung Cancer With EGFR Mutation | Phase 1 | 2024-12-13 |
| Not Yet Recruiting | A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volu Healthy | Phase 1 | 2024-07-01 |
| Not Yet Recruiting | Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Non-Small Cell Lung Cancer、EGFR Sensitive Mutation | Phase 1 | 2023-09-01 |
| Unknown | BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2023-05-16 |
| Unknown | A Study of BPI-452080 in Subjects With Solid Tumors Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease | Phase 1 | 2023-04-28 |
| Recruiting | A Study of BPI-460372 in Advanced Solid Tumor Patients Advanced Solid Tumor | Phase 1 | 2023-04-24 |
| Recruiting | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy | Phase 3 | 2023-03-28 |
| Recruiting | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma Advanced Solid Tumor, Lymphoma, NSCLC | Phase 1 | 2022-08-29 |
| Unknown | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | 2022-06-01 |
| Unknown | A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurren Breast Cancer | Phase 3 | 2022-05-25 |
| Recruiting | Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer Non-small Cell Lung Cancer | Phase 3 | 2022-05-24 |
| Completed | A Food-Effect Study of BPI-16350 in Healthy Subjects Healthy | Phase 1 | 2022-04-15 |
| Unknown | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 Advanced Solid Tumor | Phase 1 | 2022-01-19 |
| Recruiting | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer | Phase 1 / Phase 2 | 2021-09-24 |
| Unknown | A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors Malignant Neoplasms, Metastatic Cancer | Phase 1 | 2021-08-24 |
| Active Not Recruiting | Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer Non-Small Cell Lung Cancer | Phase 2 | 2021-08-12 |
| Unknown | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2021-07-21 |
| Unknown | A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia Leukemia | Phase 1 / Phase 2 | 2021-07-01 |
| Unknown | A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors Metastasis, Neoplasm | Phase 1 | 2021-03-22 |
| Unknown | The Absorption, Metabolism and Excretion of [14C]D-0316 in Human Advanced or Metastatic Non-small Cell Lung | Phase 1 | 2020-12-05 |
| Completed | D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCL Non-Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 / Phase 3 | 2019-12-24 |
| Active Not Recruiting | A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor Advanced Solid Cancer | Phase 1 | 2019-07-18 |
| Unknown | X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases Lung Cancer, Nonsmall Cell, Brain Metastases | Phase 2 | 2019-03-21 |
| Unknown | The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human ALK-POSITIVE NSCLC | Phase 1 | 2018-12-28 |
| Unknown | Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | 2018-12-01 |
| Unknown | Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation Non-Small Cell Lung Cancer, Brain Metastases | Phase 2 | 2018-12-01 |
| Unknown | Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | 2018-10-01 |
| Unknown | A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combine Non Small Cell Lung Cancer, Brain Metastases | Phase 3 | 2018-07-20 |
| Unknown | X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement Lung Cancer, ROS1 Gene Rearrangement | Phase 2 | 2018-06-15 |
| Completed | Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers Lung Cancer | Phase 1 | 2018-06-11 |
| Unknown | Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung C EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non Small Cell Lung Cancer Stage IIIB | Phase 2 | 2018-05-09 |
| Completed | A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volun Non-Small Cell Lung Cancer | Phase 1 | 2018-03-12 |
| Terminated | Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis Mild to Moderate Psoriasis | Phase 2 | 2017-11-29 |
| Unknown | Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer Plasma EGFR Mutation-positive Lung Cancer | Phase 2 | 2017-11-18 |
| Unknown | X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib Non-Small Cell Lung Cancer | Phase 2 | 2017-09-28 |
| Unknown | Dose Escalating Study of BPI-3016 in Healthy Subjects Healthy Subject | Phase 1 | 2017-05-24 |
| Completed | Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK Solid Tumor, Non-Small Cell Lung Cancer Metastatic | Phase 1 | 2017-03-06 |
| Unknown | Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC Non-small Cell Lung Cancer | Phase 1 | 2017-03-01 |
| Completed | Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients Non-Small Cell Lung Cancer | Phase 1 | 2016-12-29 |
| Completed | Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis Psoriasis | Phase 1 | 2016-09-17 |
| Unknown | High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases Non-small Cell Lung Cancer, Brain Metastases | Phase 2 | 2016-03-01 |
| Completed | Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients Psoriasis | Phase 1 | 2015-11-26 |
| Completed | Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors Solid Tumors | Phase 1 | 2015-08-11 |
| Unknown | Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation Non-small Cell Lung Cancer | Phase 3 | 2015-06-08 |
| Unknown | High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation NSCLC | Phase 4 | 2015-04-01 |
| Unknown | A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2014-11-01 |
| Unknown | Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer Pancreatic Cancer | Phase 1 | 2014-10-01 |
| Unknown | Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 3 | 2014-09-01 |
| Unknown | Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Non-small Cell Lung Cancer | Phase 2 | 2014-08-01 |
| Unknown | Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanc EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 4 | 2014-07-01 |
| Unknown | Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Aden EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 4 | 2014-03-01 |
| Unknown | Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency Non-small Cell Lung Cancer | Phase 2 | 2014-02-01 |
| Completed | Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation Non-small Cell Lung Cancer | Phase 2 | 2014-01-01 |
| Unknown | Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI Non-small Cell Lung Cancer | Phase 1 | 2014-01-01 |
| Unknown | High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease Non-small Cell Lung Cancer | Phase 2 | 2014-01-01 |
| Unknown | Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer Pancreatic Cancer | Phase 1 | 2013-12-01 |
| Unknown | Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation Non-small-cell Lung Cancer | Phase 2 | 2013-08-01 |
| Unknown | Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Non-small-cell Lung Cancer | Phase 4 | 2013-06-01 |
| Completed | Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Posi Adenocarcinoma of the Gastroesophageal Junction, Esophageal Carcinoma | Phase 2 | 2013-05-01 |
| Unknown | Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients Non-small-cell Lung Cancer | Phase 2 | 2013-04-01 |
| Suspended | Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Non-small Cell Lung Cancer | Phase 4 | 2013-02-01 |
| Completed | Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patien NSCLC | Phase 3 | 2012-12-01 |
| Unknown | Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Trea Non-small Cell Lung Cancer | Phase 2 | 2012-09-01 |
| Unknown | Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Dis NSCLC | Phase 2 | 2012-09-01 |
| Unknown | Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 4 | 2012-08-01 |
| Unknown | First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Non-Small Cell Lung Cancer | Phase 4 | 2012-07-01 |
| Completed | Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation Non-small Cell Lung Cancer, Brain Metastases | Phase 1 / Phase 2 | 2011-12-01 |
| Completed | Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose Non-small Cell Lung Cancer | Phase 4 | 2011-09-01 |
| Completed | Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy Non-small Cell Lung Cancer | Phase 3 | 2010-03-01 |
| Completed | Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia | Phase 2 | 2009-06-01 |
| Completed | Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients Non-small Cell Lung Cancer | Phase 3 | 2009-02-01 |